ST Pharm Co.,Ltd. (KOSDAQ:237690)
South Korea · Delayed Price · Currency is KRW 122,000
-1,200 (-0.97%)
Jun 12, 2026, 3:30 PM KST
ST Pharm Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 346,223 | 331,681 | 273,751 | 284,992 | 249,322 | 165,642 |
Other Revenue | - | - | -0 | - | -0 | -0 |
| 346,223 | 331,681 | 273,751 | 284,992 | 249,322 | 165,642 | |
Revenue Growth (YoY) | 26.15% | 21.16% | -3.94% | 14.31% | 50.52% | 33.47% |
Cost of Revenue | 202,134 | 199,264 | 180,147 | 175,248 | 162,140 | 110,333 |
Gross Profit | 144,089 | 132,417 | 93,605 | 109,744 | 87,182 | 55,309 |
Selling, General & Admin | 47,587 | 47,476 | 40,069 | 41,120 | 37,665 | 28,034 |
Research & Development | 24,704 | 23,710 | 22,108 | 30,450 | 26,306 | 18,218 |
Amortization of Goodwill & Intangibles | 1,101 | 1,106 | 631.65 | 255.01 | 197.29 | 212.22 |
Other Operating Expenses | 819.72 | 855.43 | 464.7 | 1,069 | 863.35 | 761.82 |
Operating Expenses | 78,652 | 77,485 | 65,912 | 76,232 | 69,330 | 49,731 |
Operating Income | 65,437 | 54,933 | 27,693 | 33,512 | 17,851 | 5,578 |
Interest Expense | -4,036 | -4,036 | -7,738 | -6,106 | -2,868 | -5,157 |
Interest & Investment Income | 3,453 | 3,453 | 4,571 | 2,440 | 1,236 | 939.37 |
Earnings From Equity Investments | - | - | -246.09 | - | - | - |
Currency Exchange Gain (Loss) | -2,391 | -2,391 | 13,298 | 1,809 | 3,607 | 3,361 |
Other Non Operating Income (Expenses) | 5,767 | 163.3 | -5,823 | -236.68 | 683.87 | 65.55 |
EBT Excluding Unusual Items | 68,229 | 52,121 | 31,755 | 31,418 | 20,511 | 4,786 |
Gain (Loss) on Sale of Investments | 6,870 | 6,870 | 12,390 | -8,063 | -628.83 | 147.24 |
Gain (Loss) on Sale of Assets | -328.52 | -328.52 | -1,446 | -0.62 | -644.73 | -3,673 |
Asset Writedown | 60.5 | 60.5 | 47.79 | - | - | - |
Pretax Income | 74,831 | 58,723 | 42,747 | 23,354 | 19,237 | 1,260 |
Income Tax Expense | 5,777 | 4,161 | 10,283 | 5,831 | 1,721 | -2,117 |
Earnings From Continuing Operations | 69,054 | 54,562 | 32,464 | 17,523 | 17,516 | 3,377 |
Minority Interest in Earnings | -42.57 | 429.8 | 2,248 | 2,058 | 484.29 | -65.27 |
Net Income | 69,011 | 54,992 | 34,712 | 19,581 | 18,000 | 3,312 |
Net Income to Common | 69,011 | 54,992 | 34,712 | 19,581 | 18,000 | 3,312 |
Net Income Growth | 133.77% | 58.42% | 77.27% | 8.78% | 443.46% | - |
Shares Outstanding (Basic) | 20 | 20 | 20 | 19 | 19 | 19 |
Shares Outstanding (Diluted) | 22 | 21 | 20 | 19 | 19 | 19 |
Shares Change (YoY) | 9.10% | 9.95% | 3.70% | - | 0.77% | 0.05% |
EPS (Basic) | 3366.64 | 2705.98 | 1779.72 | 1041.07 | 957.00 | 177.50 |
EPS (Diluted) | 3312.63 | 2688.35 | 1779.72 | 1041.00 | 957.00 | 177.00 |
EPS Growth | 122.53% | 51.05% | 70.96% | 8.78% | 440.68% | - |
Free Cash Flow | 64,466 | -33,082 | 26,646 | -41,946 | -53,448 | -44,522 |
Free Cash Flow Per Share | 2979.58 | -1542.64 | 1366.16 | -2230.12 | -2841.64 | -2385.36 |
Gross Margin | 41.62% | 39.92% | 34.19% | 38.51% | 34.97% | 33.39% |
Operating Margin | 18.90% | 16.56% | 10.12% | 11.76% | 7.16% | 3.37% |
Profit Margin | 19.93% | 16.58% | 12.68% | 6.87% | 7.22% | 2.00% |
Free Cash Flow Margin | 18.62% | -9.97% | 9.73% | -14.72% | -21.44% | -26.88% |
EBITDA | 97,258 | 84,814 | 53,275 | 56,538 | 35,452 | 19,992 |
EBITDA Margin | 28.09% | 25.57% | 19.46% | 19.84% | 14.22% | 12.07% |
D&A For EBITDA | 31,822 | 29,881 | 25,582 | 23,027 | 17,600 | 14,414 |
EBIT | 65,437 | 54,933 | 27,693 | 33,512 | 17,851 | 5,578 |
EBIT Margin | 18.90% | 16.56% | 10.12% | 11.76% | 7.16% | 3.37% |
Effective Tax Rate | 7.72% | 7.09% | 24.05% | 24.97% | 8.95% | - |
Advertising Expenses | - | 1,250 | 1,221 | 705.83 | 324.5 | 83.11 |